/SPERM.ST

SPERM.ST Stock - Spermosens AB

Q: What is the analyst price target for SPERM.ST?

Analyst price target information is not currently available for SPERM.ST.

Q: What is SPERM.ST's market cap?

Market capitalization information is not currently available for SPERM.ST.

Healthcare|Medical - Diagnostics & Research|STO

$0.01-3.33%

$0.00 (-3.33%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.01

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SPERM.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.24

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	$38,000	$7,000
Gross Profit	$-179,000	$-169,000	$724,000	$3.63M	$811,000
Gross Margin	N/A	N/A	N/A	9539.5%	11585.7%
Operating Income	$-9,263,000	$-10,894,000	$-19,403,000	$-6,151,000	$-2,042,000
Net Income	$-10,204,000	$-12,202,000	$-12,646,000	$-6,423,000	$-2,045,000
Net Margin	N/A	N/A	N/A	-16902.6%	-29214.3%
EPS	$-0.05	$-0.15	$-0.68	$-0.22	$-0.06

Company Overview

Spermosens AB engages in the research, development, and commercialization of diagnostic technology in health and medical care in Sweden. The company provides male infertility fertility diagnostics and fertility treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. The company was incorporated in 2018 and is based in Lund, Sweden.

Visit Website

Earnings History & Surprises

SPERM.ST

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.05

Q4 2023

EPS Surprise History

Q4 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Dec 31, 2023	—	$-0.05	—	—

Frequently Asked Questions about SPERM.ST

What is SPERM.ST's current stock price?

Spermosens AB (SPERM.ST) is currently trading at $0.01 per share. The stock has moved -3.33% today.

What is the analyst price target for SPERM.ST?

No analyst price targets are currently available for this stock.

What sector is Spermosens AB in?

Spermosens AB operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the STO exchange.

What is SPERM.ST's market cap?

Spermosens AB has a market capitalization of $0.02 billion, making it a small-cap company.

Does SPERM.ST pay dividends?

No, Spermosens AB does not currently pay a dividend to shareholders.